Launched in 2008, ENTEREG® (alvimopan) is the first and only FDA-approved therapy to accelerate the time to upper and lower gastrointestinal recovery following partial large- or small-bowel resection surgery with primary anastomosis. ENTEREG is an oral, peripherally-acting mu-opioid receptor antagonist. ENTEREG is available only for short-term (15 doses) use in hospitalized patients. Only hospitals that have registered in and met all of the requirements for the ENTEREG Access Support and Education (E.A.S.E.®) program may use ENTEREG. For more information on ENTEREG, including its full prescribing information, the Boxed Warning regarding short-term hospital use and the E.A.S.E. Program, visit www.ENTEREG.com.
If you have any questions, please contact Cubist Pharmaceuticals at 1‑877‑282‑4786